Humacyte is trading at $0.49, up 5.30%, with no clear company-specific catalyst identified for its October 29 gain. - Its latest listed company releases were dated October 23 and October 15. - On October 28, Humacyte announced a new U.S. patent covering Symvess manufacturing and related processes; available reporting does not establish it drove the next day’s move. - Major U.S. indices were lower, offering no same-direction broad-market explanation for Humacyte’s rise.